Selected research
Market Analysis & Forecast
Global External Anti-infective Preparations Market Analysis and Forecast 2026-2032
Market perspective
The global External Anti-infective Preparations market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for External Anti-infective Preparations is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for External Anti-infective Preparations is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for External Anti-infective Preparations is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for External Anti-infective Preparations is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of External Anti-infective Preparations include SK-SF, Zhejiang Funo Pharmaceuticals, Teva, Sun Pharmaceutical, Shandong Jingwei Pharmaceuticals, Sandoz, J & J, Liaoning Xingao Pharmaceuticals and Jiangsu Zhiyuan Pharmaceuticals, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for External Anti-infective Preparations, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of External Anti-infective Preparations, also provides the revenue of main regions and countries. Of the upcoming market potential for External Anti-infective Preparations, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the External Anti-infective Preparations revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global External Anti-infective Preparations market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for External Anti-infective Preparations revenue, projected growth trends, production technology, application and end-user industry.
External Anti-infective Preparations Segment by Company
SK-SF
Zhejiang Funo Pharmaceuticals
Teva
Sun Pharmaceutical
Shandong Jingwei Pharmaceuticals
Sandoz
J & J
Liaoning Xingao Pharmaceuticals
Jiangsu Zhiyuan Pharmaceuticals
Jiangsu Fubang Pharmaceuticals
Hubei Renfu
Bayer
STADA Arzneimittel
LEO Pharma
Kaken Pharmaceutical
Haleon
Glenmark Pharmaceuticals
Galderma
Bausch Health
Almirall
External Anti-infective Preparations Segment by Type
Ointment
Solution
Gel
Other
External Anti-infective Preparations Segment by Application
Hospital
Retail Phamracy
Other
External Anti-infective Preparations Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global External Anti-infective Preparations market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of External Anti-infective Preparations and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of External Anti-infective Preparations.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of External Anti-infective Preparations in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of External Anti-infective Preparations company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, External Anti-infective Preparations revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
List of Tables
Table 1. Global External Anti-infective Preparations Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032
Table 2. Ointment Major Player
Table 3. Solution Major Player
Table 4. Gel Major Player
Table 5. Other Major Player
Table 6. Global External Anti-infective Preparations Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032
Table 7. Hospital Major Player
Table 8. Retail Phamracy Major Player
Table 9. Other Major Player
Table 10. External Anti-infective Preparations Industry Trends
Table 11. External Anti-infective Preparations Industry Drivers
Table 12. External Anti-infective Preparations Industry Opportunities and Challenges
Table 13. External Anti-infective Preparations Industry Restraints
Table 14. Global External Anti-infective Preparations Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032
Table 15. Global External Anti-infective Preparations Market Size by Region (2021-2026) & (US$ Million)
Table 16. Global External Anti-infective Preparations Market Share by Region (2021-2026)
Table 17. Global External Anti-infective Preparations Market Size by Region (2027-2032) & (US$ Million)
Table 18. Global External Anti-infective Preparations Market Share by Region (2027-2032)
Table 19. Global External Anti-infective Preparations Revenue by Players (US$ Million) & (2021-2026)
Table 20. Global External Anti-infective Preparations Revenue Market Share by Players (2021-2026)
Table 21. Global External Anti-infective Preparations Key Players Ranking, 2024 VS 2025 VS 2026
Table 22. Global External Anti-infective Preparations Key Players Headquarters & Area Served
Table 23. Global External Anti-infective Preparations Players, Product Type & Application
Table 24. Global External Anti-infective Preparations Players Establishment Date
Table 25. Global Players Market Concentration Ratio (CR5 and HHI)
Table 26. Global External Anti-infective Preparations by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 27. Global External Anti-infective Preparations Revenue by Type 2021 VS 2025 VS 2032 (US$ Million)
Table 28. Global External Anti-infective Preparations Revenue by Type (2021-2026) & (US$ Million)
Table 29. Global External Anti-infective Preparations Revenue by Type (2027-2032) & (US$ Million)
Table 30. Global External Anti-infective Preparations Revenue Market Share by Type (2021-2026)
Table 31. Global External Anti-infective Preparations Revenue Market Share by Type (2027-2032)
Table 32. Global External Anti-infective Preparations Revenue by Application 2021 VS 2025 VS 2032 (US$ Million)
Table 33. Global External Anti-infective Preparations Revenue by Application (2021-2026) & (US$ Million)
Table 34. Global External Anti-infective Preparations Revenue by Application (2027-2032) & (US$ Million)
Table 35. Global External Anti-infective Preparations Revenue Market Share by Application (2021-2026)
Table 36. Global External Anti-infective Preparations Revenue Market Share by Application (2027-2032)
Table 37. SK-SF Company Information
Table 38. SK-SF Business Overview
Table 39. SK-SF External Anti-infective Preparations Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 40. SK-SF External Anti-infective Preparations Product Portfolio
Table 41. SK-SF Recent Development
Table 42. Zhejiang Funo Pharmaceuticals Company Information
Table 43. Zhejiang Funo Pharmaceuticals Business Overview
Table 44. Zhejiang Funo Pharmaceuticals External Anti-infective Preparations Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 45. Zhejiang Funo Pharmaceuticals External Anti-infective Preparations Product Portfolio
Table 46. Zhejiang Funo Pharmaceuticals Recent Development
Table 47. Teva Company Information
Table 48. Teva Business Overview
Table 49. Teva External Anti-infective Preparations Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 50. Teva External Anti-infective Preparations Product Portfolio
Table 51. Teva Recent Development
Table 52. Sun Pharmaceutical Company Information
Table 53. Sun Pharmaceutical Business Overview
Table 54. Sun Pharmaceutical External Anti-infective Preparations Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 55. Sun Pharmaceutical External Anti-infective Preparations Product Portfolio
Table 56. Sun Pharmaceutical Recent Development
Table 57. Shandong Jingwei Pharmaceuticals Company Information
Table 58. Shandong Jingwei Pharmaceuticals Business Overview
Table 59. Shandong Jingwei Pharmaceuticals External Anti-infective Preparations Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 60. Shandong Jingwei Pharmaceuticals External Anti-infective Preparations Product Portfolio
Table 61. Shandong Jingwei Pharmaceuticals Recent Development
Table 62. Sandoz Company Information
Table 63. Sandoz Business Overview
Table 64. Sandoz External Anti-infective Preparations Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 65. Sandoz External Anti-infective Preparations Product Portfolio
Table 66. Sandoz Recent Development
Table 67. J & J Company Information
Table 68. J & J Business Overview
Table 69. J & J External Anti-infective Preparations Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 70. J & J External Anti-infective Preparations Product Portfolio
Table 71. J & J Recent Development
Table 72. Liaoning Xingao Pharmaceuticals Company Information
Table 73. Liaoning Xingao Pharmaceuticals Business Overview
Table 74. Liaoning Xingao Pharmaceuticals External Anti-infective Preparations Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 75. Liaoning Xingao Pharmaceuticals External Anti-infective Preparations Product Portfolio
Table 76. Liaoning Xingao Pharmaceuticals Recent Development
Table 77. Jiangsu Zhiyuan Pharmaceuticals Company Information
Table 78. Jiangsu Zhiyuan Pharmaceuticals Business Overview
Table 79. Jiangsu Zhiyuan Pharmaceuticals External Anti-infective Preparations Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 80. Jiangsu Zhiyuan Pharmaceuticals External Anti-infective Preparations Product Portfolio
Table 81. Jiangsu Zhiyuan Pharmaceuticals Recent Development
Table 82. Jiangsu Fubang Pharmaceuticals Company Information
Table 83. Jiangsu Fubang Pharmaceuticals Business Overview
Table 84. Jiangsu Fubang Pharmaceuticals External Anti-infective Preparations Revenue and Gross Margin (US$ Million) & (2021-2026)
Table 85. Jiangsu Fubang Pharmaceuticals External Anti-infective Preparations Product Portfolio
Table 86. Jiangsu Fubang Pharmaceuticals Recent Development
Table 87. Hubei Renfu Company Information
Table 88. Hubei Renfu Business Overview
Table 89. Hubei Renfu External Anti-infective Preparations Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 90. Hubei Renfu External Anti-infective Preparations Product Portfolio
Table 91. Hubei Renfu Recent Development
Table 92. Bayer Company Information
Table 93. Bayer Business Overview
Table 94. Bayer External Anti-infective Preparations Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 95. Bayer External Anti-infective Preparations Product Portfolio
Table 96. Bayer Recent Development
Table 97. STADA Arzneimittel Company Information
Table 98. STADA Arzneimittel Business Overview
Table 99. STADA Arzneimittel External Anti-infective Preparations Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 100. STADA Arzneimittel External Anti-infective Preparations Product Portfolio
Table 101. STADA Arzneimittel Recent Development
Table 102. LEO Pharma Company Information
Table 103. LEO Pharma Business Overview
Table 104. LEO Pharma External Anti-infective Preparations Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 105. LEO Pharma External Anti-infective Preparations Product Portfolio
Table 106. LEO Pharma Recent Development
Table 107. Kaken Pharmaceutical Company Information
Table 108. Kaken Pharmaceutical Business Overview
Table 109. Kaken Pharmaceutical External Anti-infective Preparations Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 110. Kaken Pharmaceutical External Anti-infective Preparations Product Portfolio
Table 111. Kaken Pharmaceutical Recent Development
Table 112. Haleon Company Information
Table 113. Haleon Business Overview
Table 114. Haleon External Anti-infective Preparations Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 115. Haleon External Anti-infective Preparations Product Portfolio
Table 116. Haleon Recent Development
Table 117. Glenmark Pharmaceuticals Company Information
Table 118. Glenmark Pharmaceuticals Business Overview
Table 119. Glenmark Pharmaceuticals External Anti-infective Preparations Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 120. Glenmark Pharmaceuticals External Anti-infective Preparations Product Portfolio
Table 121. Glenmark Pharmaceuticals Recent Development
Table 122. Galderma Company Information
Table 123. Galderma Business Overview
Table 124. Galderma External Anti-infective Preparations Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 125. Galderma External Anti-infective Preparations Product Portfolio
Table 126. Galderma Recent Development
Table 127. Bausch Health Company Information
Table 128. Bausch Health Business Overview
Table 129. Bausch Health External Anti-infective Preparations Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 130. Bausch Health External Anti-infective Preparations Product Portfolio
Table 131. Bausch Health Recent Development
Table 132. Almirall Company Information
Table 133. Almirall Business Overview
Table 134. Almirall External Anti-infective Preparations Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026)
Table 135. Almirall External Anti-infective Preparations Product Portfolio
Table 136. Almirall Recent Development
Table 137. North America External Anti-infective Preparations Revenue by Type (2021-2026) & (US$ Million)
Table 138. North America External Anti-infective Preparations Revenue by Type (2027-2032) & (US$ Million)
Table 139. North America External Anti-infective Preparations Revenue by Application (2021-2026) & (US$ Million)
Table 140. North America External Anti-infective Preparations Revenue by Application (2027-2032) & (US$ Million)
Table 141. North America External Anti-infective Preparations Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million)
Table 142. North America External Anti-infective Preparations Revenue by Country (2021-2026) & (US$ Million)
Table 143. North America External Anti-infective Preparations Revenue by Country (US$ Million) & (2027-2032)
Table 144. Europe External Anti-infective Preparations Revenue by Type (2021-2026) & (US$ Million)
Table 145. Europe External Anti-infective Preparations Revenue by Type (2027-2032) & (US$ Million)
Table 146. Europe External Anti-infective Preparations Revenue by Application (2021-2026) & (US$ Million)
Table 147. Europe External Anti-infective Preparations Revenue by Application (2027-2032) & (US$ Million)
Table 148. Europe External Anti-infective Preparations Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million)
Table 149. Europe External Anti-infective Preparations Revenue by Country (2021-2026) & (US$ Million)
Table 150. Europe External Anti-infective Preparations Revenue by Country (US$ Million) & (2027-2032)
Table 151. China External Anti-infective Preparations Revenue by Type (2021-2026) & (US$ Million)
Table 152. China External Anti-infective Preparations Revenue by Type (2027-2032) & (US$ Million)
Table 153. China External Anti-infective Preparations Revenue by Application (2021-2026) & (US$ Million)
Table 154. China External Anti-infective Preparations Revenue by Application (2027-2032) & (US$ Million)
Table 155. Asia External Anti-infective Preparations Revenue by Type (2021-2026) & (US$ Million)
Table 156. Asia External Anti-infective Preparations Revenue by Type (2027-2032) & (US$ Million)
Table 157. Asia External Anti-infective Preparations Revenue by Application (2021-2026) & (US$ Million)
Table 158. Asia External Anti-infective Preparations Revenue by Application (2027-2032) & (US$ Million)
Table 159. Asia External Anti-infective Preparations Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million)
Table 160. Asia External Anti-infective Preparations Revenue by Region (US$ Million) & (2021-2026)
Table 161. Asia External Anti-infective Preparations Revenue by Region (US$ Million) & (2027-2032)
Table 162. SAMEA External Anti-infective Preparations Revenue by Type (2021-2026) & (US$ Million)
Table 163. SAMEA External Anti-infective Preparations Revenue by Type (2027-2032) & (US$ Million)
Table 164. SAMEA External Anti-infective Preparations Revenue by Application (2021-2026) & (US$ Million)
Table 165. SAMEA External Anti-infective Preparations Revenue by Application (2027-2032) & (US$ Million)
Table 166. SAMEA External Anti-infective Preparations Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million)
Table 167. SAMEA External Anti-infective Preparations Revenue by Country (2021-2026) & (US$ Million)
Table 168. SAMEA External Anti-infective Preparations Revenue by Country (US$ Million) & (2027-2032)
Table 169. Research Programs/Design for This Report
Table 170. Authors List of This Report
Table 171. Secondary Sources
Table 172. Primary Sources
List of Figures
Figure 1. External Anti-infective Preparations Image
Figure 2. Global External Anti-infective Preparations Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032
Figure 3. Global External Anti-infective Preparations Market Size Share 2021 VS 2025 VS 2032
Figure 4. Ointment Image
Figure 5. Solution Image
Figure 6. Gel Image
Figure 7. Other Image
Figure 8. Global External Anti-infective Preparations Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032
Figure 9. Global External Anti-infective Preparations Market Size Share 2021 VS 2025 VS 2032
Figure 10. Hospital Image
Figure 11. Retail Phamracy Image
Figure 12. Other Image
Figure 13. Global External Anti-infective Preparations Market Size (US$ Million) & (2021-2032)
Figure 14. Global External Anti-infective Preparations Market Size, (US$ Million), 2021 VS 2025 VS 2032
Figure 15. Global External Anti-infective Preparations Market Share by Region: 2021 VS 2025 VS 2032
Figure 16. Global External Anti-infective Preparations Players Revenue Share Top 10 and Top 5 in 2025
Figure 17. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 18. Global External Anti-infective Preparations Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million)
Figure 19. Global External Anti-infective Preparations Revenue Market Share 2021 VS 2025 VS 2032
Figure 20. Global External Anti-infective Preparations Revenue Market Share by Type (2021-2032)
Figure 21. Global External Anti-infective Preparations Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million)
Figure 22. Global External Anti-infective Preparations Revenue Market Share by Application (2021 VS 2025 VS 2032)
Figure 23. Global External Anti-infective Preparations Revenue Market Share by Application (2021-2032)
Figure 24. North America External Anti-infective Preparations Revenue YoY Growth (2021-2032) & (US$ Million)
Figure 25. North America External Anti-infective Preparations Revenue Share by Type (2021-2032)
Figure 26. North America External Anti-infective Preparations Revenue Share by Application (2021-2032)
Figure 27. North America External Anti-infective Preparations Revenue Share by Country (2021-2032)
Figure 28. United States External Anti-infective Preparations Revenue YoY Growth (US$ Million) & (2021-2032)
Figure 29. Canada External Anti-infective Preparations Revenue YoY Growth (US$ Million) & (2021-2032)
Figure 30. Mexico External Anti-infective Preparations Revenue YoY Growth (US$ Million) & (2021-2032)
Figure 31. Europe External Anti-infective Preparations Revenue YoY Growth (2021-2032) & (US$ Million)
Figure 32. Europe External Anti-infective Preparations Revenue Share by Type (2021-2032)
Figure 33. Europe External Anti-infective Preparations Revenue Share by Application (2021-2032)
Figure 34. Europe External Anti-infective Preparations Revenue Share by Country (2021-2032)
Figure 35. Germany External Anti-infective Preparations Revenue YoY Growth (US$ Million) & (2021-2032)
Figure 36. France External Anti-infective Preparations Revenue YoY Growth (US$ Million) & (2021-2032)
Figure 37. U.K. External Anti-infective Preparations Revenue YoY Growth (US$ Million) & (2021-2032)
Figure 38. Italy External Anti-infective Preparations Revenue YoY Growth (US$ Million) & (2021-2032)
Figure 39. Spain External Anti-infective Preparations Revenue YoY Growth (US$ Million) & (2021-2032)
Figure 40. Russia External Anti-infective Preparations Revenue YoY Growth (US$ Million) & (2021-2032)
Figure 41. Netherlands External Anti-infective Preparations Revenue YoY Growth (US$ Million) & (2021-2032)
Figure 42. Nordic Countries External Anti-infective Preparations Revenue YoY Growth (US$ Million) & (2021-2032)
Figure 43. China External Anti-infective Preparations Revenue YoY Growth (2021-2032) & (US$ Million)
Figure 44. China External Anti-infective Preparations Revenue Share by Type (2021-2032)
Figure 45. China External Anti-infective Preparations Revenue Share by Application (2021-2032)
Figure 46. Asia External Anti-infective Preparations Revenue YoY Growth (2021-2032) & (US$ Million)
Figure 47. Asia External Anti-infective Preparations Revenue Share by Type (2021-2032)
Figure 48. Asia External Anti-infective Preparations Revenue Share by Application (2021-2032)
Figure 49. Asia External Anti-infective Preparations Revenue Share by Region (2021-2032)
Figure 50. Japan External Anti-infective Preparations Revenue YoY Growth (US$ Million) & (2021-2032)
Figure 51. South Korea External Anti-infective Preparations Revenue YoY Growth (US$ Million) & (2021-2032)
Figure 52. India External Anti-infective Preparations Revenue YoY Growth (US$ Million) & (2021-2032)
Figure 53. Australia External Anti-infective Preparations Revenue YoY Growth (US$ Million) & (2021-2032)
Figure 54. Taiwan External Anti-infective Preparations Revenue YoY Growth (US$ Million) & (2021-2032)
Figure 55. Southeast Asia External Anti-infective Preparations Revenue YoY Growth (US$ Million) & (2021-2032)
Figure 56. SAMEA External Anti-infective Preparations Revenue YoY Growth (2021-2032) & (US$ Million)
Figure 57. SAMEA External Anti-infective Preparations Revenue Share by Type (2021-2032)
Figure 58. SAMEA External Anti-infective Preparations Revenue Share by Application (2021-2032)
Figure 59. SAMEA External Anti-infective Preparations Revenue Share by Country (2021-2032)
Figure 60. Brazil External Anti-infective Preparations Revenue YoY Growth (US$ Million) & (2021-2032)
Figure 61. Argentina External Anti-infective Preparations Revenue YoY Growth (US$ Million) & (2021-2032)
Figure 62. Chile External Anti-infective Preparations Revenue YoY Growth (US$ Million) & (2021-2032)
Figure 63. Colombia External Anti-infective Preparations Revenue YoY Growth (US$ Million) & (2021-2032)
Figure 64. Peru External Anti-infective Preparations Revenue YoY Growth (US$ Million) & (2021-2032)
Figure 65. Saudi Arabia External Anti-infective Preparations Revenue YoY Growth (US$ Million) & (2021-2032)
Figure 66. Israel External Anti-infective Preparations Revenue YoY Growth (US$ Million) & (2021-2032)
Figure 67. UAE External Anti-infective Preparations Revenue YoY Growth (US$ Million) & (2021-2032)
Figure 68. Turkey External Anti-infective Preparations Revenue YoY Growth (US$ Million) & (2021-2032)
Figure 69. Iran External Anti-infective Preparations Revenue YoY Growth (US$ Million) & (2021-2032)
Figure 70. Egypt External Anti-infective Preparations Revenue YoY Growth (US$ Million) & (2021-2032)
Figure 71. Years Considered
Figure 72. Research Process
Figure 73. Key Executives Interviewed
Scope & coverage.
Types
- Ointment
- Solution
- Gel
- Other
Applications
- Hospital
- Retail Phamracy
- Other
Companies covered
- SK-SF
- Zhejiang Funo Pharmaceuticals
- Teva
- Sun Pharmaceutical
- Shandong Jingwei Pharmaceuticals
- Sandoz
- J & J
- Liaoning Xingao Pharmaceuticals
- Jiangsu Zhiyuan Pharmaceuticals
- Jiangsu Fubang Pharmaceuticals
- Hubei Renfu
- Bayer
- STADA Arzneimittel
- LEO Pharma
- Kaken Pharmaceutical
- Haleon
- Glenmark Pharmaceuticals
- Galderma
- Bausch Health
- Almirall
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 External Anti-infective Preparations Market by Type
- 1.2.1 Global External Anti-infective Preparations Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Ointment
- 1.2.3 Solution
- 1.2.4 Gel
- 1.2.5 Other
- 1.3 External Anti-infective Preparations Market by Application
- 1.3.1 Global External Anti-infective Preparations Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Hospital
- 1.3.3 Retail Phamracy
- 1.3.4 Other
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 External Anti-infective Preparations Market Dynamics
- 2.1 External Anti-infective Preparations Industry Trends
- 2.2 External Anti-infective Preparations Industry Drivers
- 2.3 External Anti-infective Preparations Industry Opportunities and Challenges
- 2.4 External Anti-infective Preparations Industry Restraints
3 Global Growth Perspective
- 3.1 Global External Anti-infective Preparations Market Perspective (2021-2032)
- 3.2 Global External Anti-infective Preparations Growth Trends by Region
- 3.2.1 Global External Anti-infective Preparations Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global External Anti-infective Preparations Market Size by Region (2021-2026)
- 3.2.3 Global External Anti-infective Preparations Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global External Anti-infective Preparations Revenue by Players
- 4.1.1 Global External Anti-infective Preparations Revenue by Players (2021-2026)
- 4.1.2 Global External Anti-infective Preparations Revenue Market Share by Players (2021-2026)
- 4.1.3 Global External Anti-infective Preparations Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global External Anti-infective Preparations Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global External Anti-infective Preparations Key Players Headquarters & Area Served
- 4.4 Global External Anti-infective Preparations Players, Product Type & Application
- 4.5 Global External Anti-infective Preparations Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global External Anti-infective Preparations Market CR5 and HHI
- 4.6.3 2025 External Anti-infective Preparations Tier 1, Tier 2, and Tier 3
5 External Anti-infective Preparations Market Size by Type
- 5.1 Global External Anti-infective Preparations Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global External Anti-infective Preparations Revenue by Type (2021-2032)
- 5.3 Global External Anti-infective Preparations Revenue Market Share by Type (2021-2032)
6 External Anti-infective Preparations Market Size by Application
- 6.1 Global External Anti-infective Preparations Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global External Anti-infective Preparations Revenue by Application (2021-2032)
- 6.3 Global External Anti-infective Preparations Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 SK-SF
- 7.1.1 SK-SF Company Information
- 7.1.2 SK-SF Business Overview
- 7.1.3 SK-SF External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
- 7.1.4 SK-SF External Anti-infective Preparations Product Portfolio
- 7.1.5 SK-SF Recent Developments
- 7.2 Zhejiang Funo Pharmaceuticals
- 7.2.1 Zhejiang Funo Pharmaceuticals Company Information
- 7.2.2 Zhejiang Funo Pharmaceuticals Business Overview
- 7.2.3 Zhejiang Funo Pharmaceuticals External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
- 7.2.4 Zhejiang Funo Pharmaceuticals External Anti-infective Preparations Product Portfolio
- 7.2.5 Zhejiang Funo Pharmaceuticals Recent Developments
- 7.3 Teva
- 7.3.1 Teva Company Information
- 7.3.2 Teva Business Overview
- 7.3.3 Teva External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
- 7.3.4 Teva External Anti-infective Preparations Product Portfolio
- 7.3.5 Teva Recent Developments
- 7.4 Sun Pharmaceutical
- 7.4.1 Sun Pharmaceutical Company Information
- 7.4.2 Sun Pharmaceutical Business Overview
- 7.4.3 Sun Pharmaceutical External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
- 7.4.4 Sun Pharmaceutical External Anti-infective Preparations Product Portfolio
- 7.4.5 Sun Pharmaceutical Recent Developments
- 7.5 Shandong Jingwei Pharmaceuticals
- 7.5.1 Shandong Jingwei Pharmaceuticals Company Information
- 7.5.2 Shandong Jingwei Pharmaceuticals Business Overview
- 7.5.3 Shandong Jingwei Pharmaceuticals External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
- 7.5.4 Shandong Jingwei Pharmaceuticals External Anti-infective Preparations Product Portfolio
- 7.5.5 Shandong Jingwei Pharmaceuticals Recent Developments
- 7.6 Sandoz
- 7.6.1 Sandoz Company Information
- 7.6.2 Sandoz Business Overview
- 7.6.3 Sandoz External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
- 7.6.4 Sandoz External Anti-infective Preparations Product Portfolio
- 7.6.5 Sandoz Recent Developments
- 7.7 J & J
- 7.7.1 J & J Company Information
- 7.7.2 J & J Business Overview
- 7.7.3 J & J External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
- 7.7.4 J & J External Anti-infective Preparations Product Portfolio
- 7.7.5 J & J Recent Developments
- 7.8 Liaoning Xingao Pharmaceuticals
- 7.8.1 Liaoning Xingao Pharmaceuticals Company Information
- 7.8.2 Liaoning Xingao Pharmaceuticals Business Overview
- 7.8.3 Liaoning Xingao Pharmaceuticals External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
- 7.8.4 Liaoning Xingao Pharmaceuticals External Anti-infective Preparations Product Portfolio
- 7.8.5 Liaoning Xingao Pharmaceuticals Recent Developments
- 7.9 Jiangsu Zhiyuan Pharmaceuticals
- 7.9.1 Jiangsu Zhiyuan Pharmaceuticals Company Information
- 7.9.2 Jiangsu Zhiyuan Pharmaceuticals Business Overview
- 7.9.3 Jiangsu Zhiyuan Pharmaceuticals External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
- 7.9.4 Jiangsu Zhiyuan Pharmaceuticals External Anti-infective Preparations Product Portfolio
- 7.9.5 Jiangsu Zhiyuan Pharmaceuticals Recent Developments
- 7.10 Jiangsu Fubang Pharmaceuticals
- 7.10.1 Jiangsu Fubang Pharmaceuticals Company Information
- 7.10.2 Jiangsu Fubang Pharmaceuticals Business Overview
- 7.10.3 Jiangsu Fubang Pharmaceuticals External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
- 7.10.4 Jiangsu Fubang Pharmaceuticals External Anti-infective Preparations Product Portfolio
- 7.10.5 Jiangsu Fubang Pharmaceuticals Recent Developments
- 7.11 Hubei Renfu
- 7.11.1 Hubei Renfu Company Information
- 7.11.2 Hubei Renfu Business Overview
- 7.11.3 Hubei Renfu External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
- 7.11.4 Hubei Renfu External Anti-infective Preparations Product Portfolio
- 7.11.5 Hubei Renfu Recent Developments
- 7.12 Bayer
- 7.12.1 Bayer Company Information
- 7.12.2 Bayer Business Overview
- 7.12.3 Bayer External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
- 7.12.4 Bayer External Anti-infective Preparations Product Portfolio
- 7.12.5 Bayer Recent Developments
- 7.13 STADA Arzneimittel
- 7.13.1 STADA Arzneimittel Company Information
- 7.13.2 STADA Arzneimittel Business Overview
- 7.13.3 STADA Arzneimittel External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
- 7.13.4 STADA Arzneimittel External Anti-infective Preparations Product Portfolio
- 7.13.5 STADA Arzneimittel Recent Developments
- 7.14 LEO Pharma
- 7.14.1 LEO Pharma Company Information
- 7.14.2 LEO Pharma Business Overview
- 7.14.3 LEO Pharma External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
- 7.14.4 LEO Pharma External Anti-infective Preparations Product Portfolio
- 7.14.5 LEO Pharma Recent Developments
- 7.15 Kaken Pharmaceutical
- 7.15.1 Kaken Pharmaceutical Company Information
- 7.15.2 Kaken Pharmaceutical Business Overview
- 7.15.3 Kaken Pharmaceutical External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
- 7.15.4 Kaken Pharmaceutical External Anti-infective Preparations Product Portfolio
- 7.15.5 Kaken Pharmaceutical Recent Developments
- 7.16 Haleon
- 7.16.1 Haleon Company Information
- 7.16.2 Haleon Business Overview
- 7.16.3 Haleon External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
- 7.16.4 Haleon External Anti-infective Preparations Product Portfolio
- 7.16.5 Haleon Recent Developments
- 7.17 Glenmark Pharmaceuticals
- 7.17.1 Glenmark Pharmaceuticals Company Information
- 7.17.2 Glenmark Pharmaceuticals Business Overview
- 7.17.3 Glenmark Pharmaceuticals External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
- 7.17.4 Glenmark Pharmaceuticals External Anti-infective Preparations Product Portfolio
- 7.17.5 Glenmark Pharmaceuticals Recent Developments
- 7.18 Galderma
- 7.18.1 Galderma Company Information
- 7.18.2 Galderma Business Overview
- 7.18.3 Galderma External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
- 7.18.4 Galderma External Anti-infective Preparations Product Portfolio
- 7.18.5 Galderma Recent Developments
- 7.19 Bausch Health
- 7.19.1 Bausch Health Company Information
- 7.19.2 Bausch Health Business Overview
- 7.19.3 Bausch Health External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
- 7.19.4 Bausch Health External Anti-infective Preparations Product Portfolio
- 7.19.5 Bausch Health Recent Developments
- 7.20 Almirall
- 7.20.1 Almirall Company Information
- 7.20.2 Almirall Business Overview
- 7.20.3 Almirall External Anti-infective Preparations Revenue and Gross Margin (2021-2026)
- 7.20.4 Almirall External Anti-infective Preparations Product Portfolio
- 7.20.5 Almirall Recent Developments
8 North America
- 8.1 North America External Anti-infective Preparations Revenue (2021-2032)
- 8.2 North America External Anti-infective Preparations Revenue by Type (2021-2032)
- 8.2.1 North America External Anti-infective Preparations Revenue by Type (2021-2026)
- 8.2.2 North America External Anti-infective Preparations Revenue by Type (2027-2032)
- 8.3 North America External Anti-infective Preparations Revenue Share by Type (2021-2032)
- 8.4 North America External Anti-infective Preparations Revenue by Application (2021-2032)
- 8.4.1 North America External Anti-infective Preparations Revenue by Application (2021-2026)
- 8.4.2 North America External Anti-infective Preparations Revenue by Application (2027-2032)
- 8.5 North America External Anti-infective Preparations Revenue Share by Application (2021-2032)
- 8.6 North America External Anti-infective Preparations Revenue by Country
- 8.6.1 North America External Anti-infective Preparations Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America External Anti-infective Preparations Revenue by Country (2021-2026)
- 8.6.3 North America External Anti-infective Preparations Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe External Anti-infective Preparations Revenue (2021-2032)
- 9.2 Europe External Anti-infective Preparations Revenue by Type (2021-2032)
- 9.2.1 Europe External Anti-infective Preparations Revenue by Type (2021-2026)
- 9.2.2 Europe External Anti-infective Preparations Revenue by Type (2027-2032)
- 9.3 Europe External Anti-infective Preparations Revenue Share by Type (2021-2032)
- 9.4 Europe External Anti-infective Preparations Revenue by Application (2021-2032)
- 9.4.1 Europe External Anti-infective Preparations Revenue by Application (2021-2026)
- 9.4.2 Europe External Anti-infective Preparations Revenue by Application (2027-2032)
- 9.5 Europe External Anti-infective Preparations Revenue Share by Application (2021-2032)
- 9.6 Europe External Anti-infective Preparations Revenue by Country
- 9.6.1 Europe External Anti-infective Preparations Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe External Anti-infective Preparations Revenue by Country (2021-2026)
- 9.6.3 Europe External Anti-infective Preparations Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China External Anti-infective Preparations Revenue (2021-2032)
- 10.2 China External Anti-infective Preparations Revenue by Type (2021-2032)
- 10.2.1 China External Anti-infective Preparations Revenue by Type (2021-2026)
- 10.2.2 China External Anti-infective Preparations Revenue by Type (2027-2032)
- 10.3 China External Anti-infective Preparations Revenue Share by Type (2021-2032)
- 10.4 China External Anti-infective Preparations Revenue by Application (2021-2032)
- 10.4.1 China External Anti-infective Preparations Revenue by Application (2021-2026)
- 10.4.2 China External Anti-infective Preparations Revenue by Application (2027-2032)
- 10.5 China External Anti-infective Preparations Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia External Anti-infective Preparations Revenue (2021-2032)
- 11.2 Asia External Anti-infective Preparations Revenue by Type (2021-2032)
- 11.2.1 Asia External Anti-infective Preparations Revenue by Type (2021-2026)
- 11.2.2 Asia External Anti-infective Preparations Revenue by Type (2027-2032)
- 11.3 Asia External Anti-infective Preparations Revenue Share by Type (2021-2032)
- 11.4 Asia External Anti-infective Preparations Revenue by Application (2021-2032)
- 11.4.1 Asia External Anti-infective Preparations Revenue by Application (2021-2026)
- 11.4.2 Asia External Anti-infective Preparations Revenue by Application (2027-2032)
- 11.5 Asia External Anti-infective Preparations Revenue Share by Application (2021-2032)
- 11.6 Asia External Anti-infective Preparations Revenue by Country
- 11.6.1 Asia External Anti-infective Preparations Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia External Anti-infective Preparations Revenue by Country (2021-2026)
- 11.6.3 Asia External Anti-infective Preparations Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA External Anti-infective Preparations Revenue (2021-2032)
- 12.2 SAMEA External Anti-infective Preparations Revenue by Type (2021-2032)
- 12.2.1 SAMEA External Anti-infective Preparations Revenue by Type (2021-2026)
- 12.2.2 SAMEA External Anti-infective Preparations Revenue by Type (2027-2032)
- 12.3 SAMEA External Anti-infective Preparations Revenue Share by Type (2021-2032)
- 12.4 SAMEA External Anti-infective Preparations Revenue by Application (2021-2032)
- 12.4.1 SAMEA External Anti-infective Preparations Revenue by Application (2021-2026)
- 12.4.2 SAMEA External Anti-infective Preparations Revenue by Application (2027-2032)
- 12.5 SAMEA External Anti-infective Preparations Revenue Share by Application (2021-2032)
- 12.6 SAMEA External Anti-infective Preparations Revenue by Country
- 12.6.1 SAMEA External Anti-infective Preparations Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA External Anti-infective Preparations Revenue by Country (2021-2026)
- 12.6.3 SAMEA External Anti-infective Preparations Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
$4,950USD
Buy nowPDF by email within 3–5 working days after payment confirmation.
Talk to an analyst